[Angiogenesis and anti-angiogenic strategies for glioblastoma].
The poor prognosis of patients with glioblastoma multiforme in spite of aggressive conventional anticancer therapies has led to the search for new therapeutic strategies. As glioblastomas are highly vascularized and their growth is angiogenesis-dependent, the inhibition of the sprouting of new capillaries from preexisting blood vessels is one of the most promising therapeutic approaches. Different anti-angiogenic strategies have been developed: inhibition of pro-angiogenic factors and/or receptors and/or downstream cell signaling, inactivation of endothelial cells, inhibition of cellular adhesion molecules and/or extracellular matrix remodeling. Inhibitors of angiogenesis are separated into endogenous inhibitors such as angiostatin, trombospondin or alpha interferon and natural or synthetic inhibitors such as thalidomide, antibodies against angiogenic growth factors or inhibitors of tyrosine kinase receptors. In this review, the majority of experimental studies in glioblastoma models in vivo are summarized and clinical perspectives are discussed.
de Boüard
Sophie
S
Groupe régional d'étude sur le cancer (Grecan), Université de Caen Basse-Normandie, Centre François-Baclesse, avenue du Général-Harris, 14076 Caen Cedex 05. s.de.bouard@baclesse.fr
Guillamo
Jean-Sébastien
JS
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001932:Brain Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000532:radiotherapy; D004359:Drug Therapy, Combination; D005909:Glioblastoma / Q000098:blood supply / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D051379:Mice; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D051381:Rats
D020533:Angiogenesis Inhibitors